Sana Biotechnology will present data from multiple preclinical studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Sana Biotechnology will present data from multiple preclinical studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Healthy Biotechnology, Inc

SEATTLE, May 2, 2022 (GLOBE NEWSWIRE) – Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering drug-engineered cells, today announced that five abstracts covering preclinical data from its platforms hypoimmune and fusogenic have been accepted for oral or poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual meeting to be held May 16-19, 2022 in Washington, DC

“We will have a strong presence at ASGCT, with presentations of data from multiple technology platforms, including two oral presentations on our hypoimmune platform and two posters on our fusogen platform,” said Steve Harr, MD, President and CEO of Sana. “We are excited about the progress we are making with these platforms as they aim to address some of the major challenges faced in the field of gene and cell therapy. Our goal is to present two INDs this year from two of these platforms, with the aim of translating our exciting scientific advances into beneficial therapies for patients. “

ASGCT abstracts are publicly available at https://annualmeeting.asgct.org.

Oral presentations:

Title:

Hypoimmune mouse primary pancreatic islet cells survive and functionally rescue allogeneic diabetic mice

Summary:

Hypoimmune islet cells transplanted intramuscularly may be able to persist and function in diabetic patients without immune suppression

Abstract number:

1244

Session:

Cellular therapies for haematological disorders

Appointment:

Thursday, May 19, 2022, 10:30 a.m. to 10:45 a.m. ET

Title:

Generation of ready-to-use allogeneic hypoimmune Tregs

Summary:

A method to genetically modify “hypoimmune” evasive immune regulatory T cells (Tregs) ex vivo which, in the assays tested, are immune evasive, functional and protected by innate immune reactivity

Abstract number:

1254

Session:

Engineering, development or manufacturing of cell therapy products

Appointment:

Thursday, May 19, 2022, 11:15 a.m. to 11:30 a.m. ET

Poster presentations:

Title:

“fusosomes” targeted for in vivo delivery to T lymphocytes

Summary:

In vivo delivery of a payload of the CD19 CAR transgene with targeting CD8 or CD4 vectors in mouse models carrying tumor Nalm-6 demonstrated robust production and persistence of CAR T cells, leading to tumor eradication

Abstract number:

1081

Session:

Cancer – Immunotherapy, Cancer Vaccines III

Appointment:

Wednesday 18 May 2022 between 5.30 pm and 6.30 pm

Title:

Fusosome-targeted gene transfer to human hepatocytes

Summary:

Proof-of-principle data showing the efficient delivery of a reporter transgene to human hepatocytes in vivo using a humanized liver mouse model

Abstract number:

875

Session:

RNA virus vectors

Appointment:

Wednesday, May 18, 2022, 5:30 pm-6:30pm ET

Title:

A new VCN test that detects lentiviral vector integrations overcoming the limits caused by plasmid residues

Summary:

Data from a new test that relies on a unique digital PCR process of amplicons and droplets specific only for reverse transcription self-inactivating viral vector nucleic acids

Abstract number:

M-305

Session:

Pharmacology / toxicology studies or assay development

Appointment:

Monday, May 16, 2022, 5:30 pm-6:30pm ET

Information on the hypoimmune platform
Sana’s hypoimmune platform is designed to create cells ex vivo which can “hide” from the patient’s immune system to allow the transplantation of allogeneic cells without the need for immunosuppression. We are applying the hypoimmune technology both to pluripotent stem cells, which can then be differentiated into multiple cell types, and to allogeneic donor-derived T cells, with the aim of producing powerful and persistent CAR T cells on a large scale. Preclinical data demonstrate across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arm of the immune system by maintaining their activity. Our most advanced programs using this platform include an allogeneic CAR T program targeting CD19 + tumors and stem cell-derived pancreatic cells for patients with type 1 diabetes.

Information on the Fusogen platform
Sana is developing re-targetable fusogenes as a technology platform to enable the in vivo delivery of genetic cargoes to specific cell types. Fusogens can bind to cell surface proteins on the target cell type and, when combined with delivery vehicles to form fusosomes, deliver a genetic payload directly to the cell’s cytoplasm. We have shown in preclinical studies that we can design fusogens to specifically target different cell surface receptors that enable specific cell delivery across multiple different cell types. Our most advanced programs using this platform include in vivo CAR T cell fusosome product candidates targeting CD19 + cancer cells, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

About Healthy Biotechnology
Sana Biotechnology, Inc. focuses on creating and delivering engineered cells as medicines for patients. We share a vision to repair and control genes, replace missing or damaged cells, and make our therapies widely available to patients. We are a passionate group of people who work together to create an enduring company that changes the way the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco and Rochester. For more information on Sana biotechnology, visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company”, “we”, “us” or “our”) under federal securities laws, including those relating to the company’s vision, progress and business plans. ; expectations for its development programs, candidate products and technology platforms, including its preclinical, clinical and regulatory development plans and expectations on timing; the Company’s participation in the 2022 American Society of Gene & Cell Therapy meeting and the subject of the Company’s presentations at that meeting; the potential ability to produce modified hypoimmune pluripotent stem cells and donor-derived allogeneic T cells that survive and evade the immune system without immunosuppression and the potential efficacy of such hypoimmune cells; and the potential ability to design re-targetable fusogens that specifically target cell surface receptors which, combined with release vehicles, enable specific cell release across different cell types. All statements other than statements of historical facts contained in this press release, including but not limited to statements regarding the Company’s strategy, expectations, cash flow and future financial condition, future operations and prospects, are statements forecast. In some cases, it is possible to identify forward-looking statements based on terms such as “aim”, “anticipate”, “presuppose”, “believe”, “contemplate”, “continue”, “might”, “plan”, “due,” “estimate”, “expect”, “goal”, “mean”, “may”, “goal”, “plan”, “positioned”, “potential”, “predict”, “seek”, “should”, “target “,” will “,” would “and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections on future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the material uncertainties in these forward-looking statements, you should not rely on forward-looking statements as a forecast of future events. These statements are subject to risks and uncertainties that could materially vary actual results, including but not limited to drug development risks such as those associated with initiation, cost, timing, advancement and results of the Company’s current and future activities, research and development programs, preclinical and clinical studies, as well as the economic, market and social disturbances due to the ongoing public health crisis caused by COVID-19. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K dated March 16, 2022 Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements for any reason.

Investor Relations and Media:
Nicole Keith
Investor.relations@sana.com
media@sana.com

Leave a Comment

Your email address will not be published.